RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Eagle Pharmaceuticals Stock

Eagle Pharmaceuticals Liabilities 2024

Eagle Pharmaceuticals Liabilities

172.6 M USD

Ticker

EGRX

ISIN

US2697961082

WKN

A1XEDS

In 2024, Eagle Pharmaceuticals's total liabilities amounted to 172.6 M USD, a 123.29% difference from the 77.3 M USD total liabilities in the previous year.

Eagle Pharmaceuticals Aktienanalyse

What does Eagle Pharmaceuticals do?

Eagle Pharmaceuticals Inc was founded in 2007 and is based in New Jersey, USA. The company operates in the field of development and marketing of pharmaceutical products. History Eagle Pharmaceuticals was founded by Scott Tarriff, an experienced entrepreneur and expert in the fields of pharmacy and biotechnology. The goal was to create a company focused on developing generic drugs with improved effectiveness. Eagle Pharmaceuticals started with two products - Argatroban and Ryanodex. Argatroban is an anticoagulant used in the treatment of thrombosis. Ryanodex is a muscle relaxant for patients suffering from malignant hyperthermia. Business model Eagle Pharmaceuticals has a unique business model that sets it apart from other pharmaceutical companies. They focus on developing generic drugs with improved effectiveness instead of entirely new drugs. The company also focuses on licensing technologies rather than spending money on research and development. The company works closely with doctors and hospitals to ensure that their products meet the needs of patients. Divisions Eagle Pharmaceuticals is divided into two business segments - branded and generic products. Branded products: The company develops and distributes generic products with improved effectiveness. These include products such as Ryanodex, Bendeka, Belrapzo, and Pemetrexed. Generic products: The company has a wide range of generic products used in the areas of anticoagulants, oncology, and pain management. These include products such as Argatroban, Docetaxel, Phenylephrine HCl, and Bivalirudin. Products Argatroban: An anticoagulant used in patients with thrombosis or thromboembolic events. Ryanodex: A muscle relaxant used in patients suffering from malignant hyperthermia. Bendeka: A medication for leukemia used in combination with other chemotherapies. Belrapzo: A medication for certain types of cancer used in combination with other chemotherapies. Pemetrexed: A medication for various cancer diseases, such as lung and breast cancer. Docetaxel: A medication for various cancer diseases, such as breast cancer, lung cancer, and prostate cancer. Phenylephrine HCl: A medication for high blood pressure and bronchodilation. Bivalirudin: An anticoagulant used in patients undergoing angioplasty or coronary bypass surgery. In summary, Eagle Pharmaceuticals is an innovative pharmaceutical company that focuses on developing drugs with improved effectiveness. The company has a wide range of products in the areas of oncology, pain management, and anticoagulants. It works closely with doctors and hospitals to ensure that its products meet the needs of patients. Eagle Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Eagle Pharmaceuticals's Liabilities

Eagle Pharmaceuticals's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Eagle Pharmaceuticals's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Eagle Pharmaceuticals's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Eagle Pharmaceuticals's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Eagle Pharmaceuticals’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Eagle Pharmaceuticals stock

What is the level of liabilities of Eagle Pharmaceuticals this year?

Eagle Pharmaceuticals has a debt balance of 172.6 M USD this year.

What were the liabilities of Eagle Pharmaceuticals compared to the previous year?

The liabilities of Eagle Pharmaceuticals have increased by 123.29% increased compared to the previous year.

What are the consequences of high debt for investors of Eagle Pharmaceuticals?

High liabilities can pose a risk for investors of Eagle Pharmaceuticals, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Eagle Pharmaceuticals?

Low liabilities mean that Eagle Pharmaceuticals has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Eagle Pharmaceuticals affect the company?

An increase in liabilities of Eagle Pharmaceuticals can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Eagle Pharmaceuticals affect the company?

A decrease in the liabilities of Eagle Pharmaceuticals can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Eagle Pharmaceuticals?

Some factors that can influence the liabilities of Eagle Pharmaceuticals include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Eagle Pharmaceuticals so important for investors?

The liabilities of Eagle Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Eagle Pharmaceuticals take to modify the liabilities?

To change its liabilities, Eagle Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Eagle Pharmaceuticals pay?

Over the past 12 months, Eagle Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Eagle Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Eagle Pharmaceuticals?

The current dividend yield of Eagle Pharmaceuticals is .

When does Eagle Pharmaceuticals pay dividends?

Eagle Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Eagle Pharmaceuticals?

Eagle Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Eagle Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Eagle Pharmaceuticals located?

Eagle Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Eagle Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Eagle Pharmaceuticals from 10/25/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/25/2024.

When did Eagle Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/25/2024.

What was the dividend of Eagle Pharmaceuticals in the year 2023?

In the year 2023, Eagle Pharmaceuticals distributed 0 USD as dividends.

In which currency does Eagle Pharmaceuticals pay out the dividend?

The dividends of Eagle Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Eagle Pharmaceuticals

Our stock analysis for Eagle Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Eagle Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.